Results from a Phase 1 proof-of-concept study evaluating Takeda Pharmaceutical’s (NYSE:TAK) TAK-925, a selective orexin type-2 receptor (OX2R) agonist, in patients with narcolepsy type 1 (NT1) showed a treatment effect. The data were presented at the World Sleep Congress in Vancouver.
Participants receiving a single 9-hour intravenous administration of TAK-925 experienced increased wakefulness compared to placebo. Mean sleep latency in the Maintenance of Wakefulness Test was 22.4 – 40.0 minutes depending on the dose versus 2.9 minutes for control.
A second Phase 1 in sleep-deprived adults showed sleep latency of 25.4 – 38.8 minutes compared to 8.6 minutes for placebo.
NT1 is characterized by excessive daytime sleepiness due to the loss of orexin-producing neurons in the brain. Orexin is a hormone that regulates appetite (orexin-A) and sleep (orexin-B).
TAK-925 has Sakigake designation in Japan (akin to Breakthrough Therapy in the U.S.).
Development is ongoing.
Related ticker: Jazz Pharmaceuticals (NASDAQ:JAZZ)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.